Abstract
OBJECTIVE: Options for human immunodeficiency virus-1-infected women who are already receiving antiretroviral medications when they become pregnant include the continuation or discontinuation of the therapy during the first trimester. These two strategies are compared in terms of plasma human immunodeficiency virus viral load and CD4 cell count. STUDY DESIGN: Seventy women who attended the II Department of Obstetrics and Gynecology were identified. Four different periods for laboratory evaluations were decided: presuspension, suspension, second trimester, and third trimester. RESULTS: Thirty-two women (46%) discontinued antiretroviral therapy; 38 women (54%) did not. Whereas plasma HIV virus viral load and CD4 cell count did not significantly vary during pregnancy in patients who did not interrupt the therapy, these two variables were influenced significantly by the discontinuation of treatment (P
| Original language | English |
|---|---|
| Pages (from-to) | 545-551 |
| Number of pages | 7 |
| Journal | American Journal of Obstetrics and Gynecology |
| Volume | 189 |
| Issue number | 2 |
| Publication status | Published - Aug 2003 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
- Obstetrics and Gynaecology
Cite this
Discontinuing combination antiretroviral therapy during the first trimester of pregnancy : insights from plasma human immunodeficiency virus-1 RNA viral load and CD4 cell count. / Bucceri, A. M.; Somigliana, E.; Matrone, R.; Uberti-Foppa, C.; Viganò, P.; Vignali, M.
In: American Journal of Obstetrics and Gynecology, Vol. 189, No. 2, 08.2003, p. 545-551.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Discontinuing combination antiretroviral therapy during the first trimester of pregnancy
T2 - insights from plasma human immunodeficiency virus-1 RNA viral load and CD4 cell count.
AU - Bucceri, A. M.
AU - Somigliana, E.
AU - Matrone, R.
AU - Uberti-Foppa, C.
AU - Viganò, P.
AU - Vignali, M.
PY - 2003/8
Y1 - 2003/8
N2 - OBJECTIVE: Options for human immunodeficiency virus-1-infected women who are already receiving antiretroviral medications when they become pregnant include the continuation or discontinuation of the therapy during the first trimester. These two strategies are compared in terms of plasma human immunodeficiency virus viral load and CD4 cell count. STUDY DESIGN: Seventy women who attended the II Department of Obstetrics and Gynecology were identified. Four different periods for laboratory evaluations were decided: presuspension, suspension, second trimester, and third trimester. RESULTS: Thirty-two women (46%) discontinued antiretroviral therapy; 38 women (54%) did not. Whereas plasma HIV virus viral load and CD4 cell count did not significantly vary during pregnancy in patients who did not interrupt the therapy, these two variables were influenced significantly by the discontinuation of treatment (P
AB - OBJECTIVE: Options for human immunodeficiency virus-1-infected women who are already receiving antiretroviral medications when they become pregnant include the continuation or discontinuation of the therapy during the first trimester. These two strategies are compared in terms of plasma human immunodeficiency virus viral load and CD4 cell count. STUDY DESIGN: Seventy women who attended the II Department of Obstetrics and Gynecology were identified. Four different periods for laboratory evaluations were decided: presuspension, suspension, second trimester, and third trimester. RESULTS: Thirty-two women (46%) discontinued antiretroviral therapy; 38 women (54%) did not. Whereas plasma HIV virus viral load and CD4 cell count did not significantly vary during pregnancy in patients who did not interrupt the therapy, these two variables were influenced significantly by the discontinuation of treatment (P
UR - http://www.scopus.com/inward/record.url?scp=0142024887&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0142024887&partnerID=8YFLogxK
M3 - Article
VL - 189
SP - 545
EP - 551
JO - American Journal of Obstetrics and Gynecology
JF - American Journal of Obstetrics and Gynecology
SN - 0002-9378
IS - 2
ER -